Replies to post #6097 on Seelos Therapeutics Inc (SEEL)

[markkind]

Interesting only the big 2 mentioned Vitaros and Femprox.

The still have a pipeline tab but that must be totally on hold until Vitaros takes off

[eicoman]

looks new and looks good, consistent with the new focus on sexual health, 2 assets and 4 milestones, these are the near term revenue drivers, 1/3 of H1 is over so we should see good news in the next 30-60 days. These milestones are long over due.